ANVS — Annovis Bio Inc
Annovis Bio Inc (ANVS)
Total return is -80.7% over the past 6.5 years, 241.5 points behind SPY at 160.8%. Its deepest 1-year drawdown was 68.8%.
Annovis Bio is a clinical-stage biopharmaceutical company developing drug candidates to treat neurodegenerative diseases, including its lead product Buntanetap in phase 3 trials for Alzheimer's disease and Parkinson's disease, along with other candidates in development for traumatic brain injury, stroke, and cognitive decline. The company does not currently distribute dividends. Annovis Bio appeals to investors seeking exposure to early-stage drug development with potential for significant upside, though clinical-stage companies carry substantial risk.
ANVS key facts
- Asset type
- Stock
- Asset class
- Equity
- Inception date
- 01/29/2020
- Last close
- $1.85
- Market cap
- $74,022,848
- Average volume
- 949700.0
- Beta
- 1.187
- Payout ratio
- 0.0
- Forward P/E
- 0.0
- EPS
- $-1.71
Issuers
Issuers are only used for ETFs and CEFs.
| Tickers | Family | Dist. Freq. | Dist. Rate | Total Return | AUM |
|---|
Screener
Drag headers to reorder. Drag column edges to resize.
| Popular | Logo | Tickers | Name | Issuer | Asset Type | Dist. Frequency | AUM | Price | Avg Volume | Inception Date | Expense Ratio | Dist. Rate | Distribution Safety Score™ | Safety-Adjusted Yield | Payout Stability | Alpha | Vs SPY | Vs QQQ | TR 1M | TR 3M | TR 6M | TR YTD | TR 1Y | TR 2Y | TR 3Y | TR 5Y | TR 10Y | TR Max | Hide row |
|---|
Tickers
| Ticker | Name | Weight |
|---|
Compare ETFs and dividend investments
Add one ticker at a time or paste several — separate with commas, spaces, or “vs” (e.g. SCHD vs JEPI vs VYM).
Import tickers from a picture or X post
Pull tickers off a screenshot or an X post. Detected tickers are shown for review before adding. Images and links are processed only to detect ticker symbols and are not saved to your comparison history.
Importing tickers from a picture or an X post is a Pro feature.
Paste a link to an X (Twitter) post — we read tickers from its text and any pictures.
- Choose peers with similar goals, such as dividend income or broad-market growth.
- Check income and return. A higher yield can come with weaker price growth.
- Review risk, fees, and overlap across the investments' shared history.
Enter tickers above, paste “SCHD vs JEPI,” or choose a popular comparison.
AI-generated analysis — AI can make mistakes. Verify important information independently. Not investment advice. AI risk disclosure
Income is not the same as return. Distribution yield measures cash paid to investors; total return also includes price changes. Compare both, especially for option-income and other high-distribution funds.
Watchlist
| Select | # | Logo | Ticker | Name | Issuer | Asset Type | AUM | Expense Ratio | Inception | Dist. Frequency | Dist. Rate | Distribution Safety Score™ | Remove |
|---|
Curated watchlists
Based on your holdings
Popular Tickers
Open in ScreenerPortfolio Popularity Map
See how widely each ticker is held and how heavily its holders allocate to it.
| # | Ticker | Issuer | % of Portfolios | 7-Day Δ | Avg % of Portfolio | Dist Rate | Dist Freq | Total Return | |
|---|---|---|---|---|---|---|---|---|---|
| Loading… | |||||||||
Alpha Rankings
Was each fund worth owning, compared to just holding what it's secretly made of? Every night we build the portfolio of plain index ETFs that most closely matched each covered fund's daily total returns, then rank the funds by alpha — what they earned beyond that copycat recipe.
Loading rankings…
Alpha is a statistical estimate, not a promise — only promising and reliable leftovers are ranked. Funds whose recipe fits too poorly, whose leftover looks like noise, or that are themselves a benchmark building block are listed separately. Option-strategy effects may not be fully captured by a linear model. Nothing here is investment advice. Coverage: funds held in at least five Dividend Vision accounts (privacy-filtered — only ticker symbols are read) or searched enough in the last 30 days. A missing ticker card means the fund is not yet in the analysed set, never that its alpha is zero.